A9513 Lutetium lu 177 dotatat therapy
Also known as: Lutathera, Lu-177 DOTATATE, dotatate
Lutetium Lu-177 dotatate therapeutic injection used for neuroendocrine tumor targeted radiotherapy treatment.
In Plain Language
radioactive cancer treatment; targeted tumor therapy
Clinical Context
Used in nuclear oncology for therapeutic treatment of neuroendocrine tumors expressing somatostatin receptors.
RVU Information
CPT A9513 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
HCPCS A-codes cover medical supplies, equipment, and transport services. Documentation must establish medical necessity and include a physician order. For durable medical equipment (DME), a Certificate of Medical Necessity (CMN) or detailed written order may be required.
Specialties
Frequently Asked Questions
What is CPT code A9513?
CPT A9513 (Lutetium lu 177 dotatat therapy) is a A Codes code. Lutetium Lu-177 dotatate therapeutic injection used for neuroendocrine tumor targeted radiotherapy treatment.
Does Medicare cover A9513?
Medicare coverage for A9513 depends on medical necessity and applicable Local Coverage Determinations (LCDs). Used in nuclear oncology for therapeutic treatment of neuroendocrine tumors expressing somatostatin receptors. A physician order is typically required.
When is CPT A9513 used?
Used in nuclear oncology for therapeutic treatment of neuroendocrine tumors expressing somatostatin receptors.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.